This is an annual conference that explores pharmaceutical science and technology in the Asia-Pacific region, with topics ranging from drug discovery to regulatory issues. The conference is aimed at researchers, industry professionals, and regulators involved in the development and regulation of pharmaceuticals, and provides a forum for sharing knowledge and collaborating on new approaches to drug development and regulation.
Date
May 08, 2017 - May 10, 2017
Location
Singapore
This Congress, who's theme is "De Novo Advancements in Pharmaceutical Sciences", highlights the importance of collaboration and innovation in advancing the pharmaceutical industry in the Asia-Pacific region.
PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization.
Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.